Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors
Study Type: Treatment
Phase: II
NCTID: NCT02978625
Principal Investigator:
Benjamin Powers
ENCERT: A Phase 1 Trial Using Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Relapsed T Cell Lymphoblastic Leukemia/Lymphoma
Study Type: Treatment
Phase: I
NCTID: NCT03328104
Principal Investigator:
Kevin Ginn
A Phase I/II, Open-label Study of Oral MRT-2359 in Patients with MYC-Driven and Other Selected Solid Tumors Including Lung Cancer and Diffuse Large B-Cell Lymphoma
Study Type: Treatment
Phase: I/II
NCTID: NCT05546268
Principal Investigator:
Rahul Parikh
A Randomized Phase III trial of Nivolumab NSC 748726 IND 125462 in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
Study Type: Treatment
Phase: III
NCTID: NCT04759586
Principal Investigator:
Keith August
An Open-Label, Phase I, Multi-Center Study to Determine in Relapsed/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome or B-Cell Non-Hodgkin Lymphoma Patients the Recommended Dose of CYAD-02 After A Non-Myeloablative Preconditioning Chemotherapy Followed By A Potential CYAD-02 Consolidation Cycle for Non-Progressive Patients CYCLE-1 ? CYAD-02 NKG2D CAR-T Clinical dEvelopment
A Phase I Study Evaluating SC262, a Hypoimmune, Allogeneic CD22-directed CAR T Cell Therapy, in Relapsed and/or Refractory Non-Hodgkin?s Lymphoma VIVID
Study Type: Treatment
Phase: I
NCTID: NCT06285422
Principal Investigator:
Forat Lutfi
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Study Type: Treatment
Phase: III
NCTID: NCT02972840
Principal Investigator:
Marc Hoffmann
A Phase I Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T-Cells MT-601 Administered to Patients with Relapsed or refractory Non-Hodgkin Lymphoma NHL [APOLLO]
Study Type: Treatment
Phase: I
NCTID: NCT05798897
Principal Investigator:
Haitham Abdelhakim
Phase II Study of Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma
A Randomized Phase II study of Brentuximab Vedotin NSC 749710 and Crizotinib NSC 749005 in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma ALCL IND 117117
Study Type: Treatment
Phase: II
NCTID: NCT01979536
Principal Investigator: